ELAN Stock Forecast & Price Target

Elanco Animal Health is supported by a strong 2Q beat and raise, with revenue of $1,368M, adjusted EBITDA of $288M, and adjusted diluted EPS of $0.34, all above consensus, while FY26 guidance was lifted for revenue, EBITDA, and EPS. Its bullish case is reinforced by accelerating momentum in Zenrelia, Quattro, and Befrena, with early launch data showing ~1,400 U.S. clinics shipped Befrena, 83% of vets likely to use it, and Quattro reaching ~53% share within penetrated clinics. The company’s diversified global portfolio, #1 Pet Retail position, and confidence in a pipeline of 5 to 7 potential blockbuster innovations through 2031 support margin expansion, deleveraging, and sustained growth despite competitive and macro risks.

Elanco Animal Health is facing a negative setup as unfavorable regulatory and pipeline updates, or differentiated competitor approvals, could weaken investor confidence and pressure its growth outlook. Slower adoption of its 7 key blockbusters, rising cannibalization, and commoditization in K9 dermatology or parasiticide markets could depress sales and EPS growth below estimates, while U.S. broad-spectrum Endecto volume growth appears to have slowed from 29% to 3% in the cited period. Further, declining flea/tick/heartworm visits in Q1:26, down 3% YTD as of May ’26, raises concern that demand softness and execution risk may continue to weigh on results.